Navigation Links
Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria
Date:2/24/2010

About Valortim®

Valortim® is a fully human monoclonal antibody designed to protect against and treat anthrax infection, including inhalational anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium.  The investigational antibody is designed to target a protein component known as the anthrax Protective Antigen (PA) of the lethal toxin complex produced by the bacterium.  Preclinical studies suggest that Valortim® has the potential to provide significant protection against anthrax infection when administered prophylactically post-exposure (i.e., prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (i.e., once symptoms become evident).

Anti-toxins such as Valortim® are a key element in combating and treating anthrax infection, in addition to vaccines and antibiotics.  The Department of Health and Human Services has issued a requirement for up to 200,000 anthrax anti-toxin treatments to be included in the Strategic National Stockpile and PharmAthene believes that Valortim® is well positioned to address this need.

About Anthrax


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
2. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
3. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
6. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
7. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
8. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
9. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
10. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
11. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... CHICAGO , Sept. 23, 2014  Hill-Rom (NYSE: ... agreement with Providence Health ( Renton, WA ... new agreement expands the companies, existing relationship as Hill-Rom ... Maternal, and Bariatric capital bed frame and surface products. ... largest health systems in the U.S.  It operates 34 ...
(Date:9/23/2014)... , Sept. 23, 2014 Research ... "Biopharmaceutical and Vaccine Production Markets" report to ... many new therapies and vaccines - including products to ... are still huge challenges during the final stages of ... when and how to risk production capital to upscale ...
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3
... 10th Annual Superbugs and Superdrugs Conference on ... ... 10 Enanta Pharmaceuticals, a,leader in the development of small ... program to,evaluate a new macrolide-related drug class, Bicyclolides, in the ...
... - Strategic Collaboration with the National Cancer Institute,s NABTT ... ... 10 BiPar Sciences, Inc. today,announced the expansion of the clinical ... the most,common glioma in adults. BSI-201, the first poly ADP-ribose polymerase,(PARP) ...
Cached Medicine Technology:Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 3BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer 2
(Date:9/23/2014)... Swedish study shows that adolescents who suffer from sleep ... to succeed academically compared to those who enjoy a ... in the journal Sleep Medicine . , In ... between 12 and 19 from Uppsala County, researchers from ... habitual short sleep duration (less than 7 hours per ...
(Date:9/23/2014)... San Jose, California (PRWEB) September 23, 2014 ... – Medical transcription is the process of translating ... assessment, clinical course, therapeutic procedures, and prognosis, into ... health insurance agents, patients, and healthcare providers. With ... documentation of each patient’s condition, outsourcing of such ...
(Date:9/23/2014)... If you or a loved one ... treatment may be a challenge. Fortunately, an inventor from ... is designed to improve the experience. , He developed ... having to remove, tear or reposition their clothing. Furthermore, ... their dignity. At the same time, it safeguards their ...
(Date:9/23/2014)... be able to grow enough food there to maintain ... food in NASA,s Orion spacecraft on the year-long trip ... extreme conditions? These are questions scientists are trying to ... International Space Station (ISS). , Plant biology investigations called ... to adapt to a microgravity environment. When a crew ...
(Date:9/23/2014)... allow electrical signals to pass unhindered through new ... Texas Children,s Hospital. , A team led by ... Matteo Pasquali created the patches infused with conductive ... a sponge-like bioscaffold that contains microscopic pores and ... overcome a limitation of current patches in which ...
Breaking Medicine News(10 mins):Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 2Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 3Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Getting to the root of the problem in space 2Health News:Getting to the root of the problem in space 3Health News:Getting to the root of the problem in space 4Health News:Nanotubes help healing hearts keep the beat 2Health News:Nanotubes help healing hearts keep the beat 3
... revolutionary EnviroCool fresh air cooling system also ... air pollution, WINCHESTER, Calif., June 11 With ... on the rise, homeowners around the,country are turning to ... cool their homes: QuietCool and EnviroCool., The QuietCool ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it will ... held June 24-26, 2008 in New York,City., Walter ... Corp.,will present on Tuesday, June 24th at 10:15 am ... presentation can be accessed through,our website at http://www.hmsholdings.com/news/presentations.asp ...
... Research Group, offering hope to sufferers of asbestos-related ... today. , Special guest Karen Banton, widow of ... the group, saying: , "Today brings hope of ... asbestos exposure and ultimately a future free of ...
... Award Presented to QualityMetric Employee at Annual ... ... 11 In recognition of clinical,research to improve the understanding ... Senior Scientist with,QualityMetric(TM) Health Outcomes Solutions, was presented the 2008-2009,American ...
... Patient Share by 2012, According to a ... New Report from Decision Resources, ... the,world,s leading research and advisory firms focusing on pharmaceutical and,healthcare ... of,fistulas in a greater percentage of patients than,Centocor/Schering-Plough/Mitsubishi Tanabe,s Remicade ...
... in children may have an impact on cardiovascular functioning ... according to a research abstract that will be presented ... the Associated Professional Sleep Societies (APSS). , The study, ... of Melbourne and Monash University, Melbourne, Victoria, Australia, focused ...
Cached Medicine News:Health News:A Far Less Expensive, Green Alternative to Traditional Air Conditioning, from QuietCool 2Health News:New research group offers hope to asbestosis sufferers 2Health News:New research group offers hope to asbestosis sufferers 3Health News:QualityMetric Senior Scientist Min Yang, MD, PhD, Recipient of Prestigious Clinical Research Award in Women's Health 2Health News:QualityMetric Senior Scientist Min Yang, MD, PhD, Recipient of Prestigious Clinical Research Award in Women's Health 3Health News:A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market 2Health News:Primary snoring in children impacts cardiovascular functioning 2Health News:Primary snoring in children impacts cardiovascular functioning 3
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
Thermal Cautery, Sterile Single-Use Units for Vasectomy. Burns at approximately 1200C (2200 F). Integrated unit includes handle, vasectomy tip, & AA batteries. Box of 10 units. Discounts on 2 or more...
Non-Cantilevered Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring diameter approximately 3.0 mm....
... earmolds add comfort and enhance hearing abilities ... paramedics, Flight-for-Life helicopter personnel, emergency technicians and ... specific in design and can be fabricated ... in today's industry to ensure clear sound ...
Medicine Products: